Mobile

A multicenter, randomized, double-blind, placebo-controlled Phase IIb Efficacy Study of Vx-001, a peptide-based cancer vaccine aimed to maintain disease control after first line treatment in HLA-A*0...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-005968-24

A multicenter, randomized, double-blind, placebo-controlled Phase IIb Efficacy Study of Vx-001, a peptide-based cancer vaccine aimed to maintain disease control after first line treatment in HLA-A*0201 positive patients with TERT positive NSCLC (stage IV or recurrent stage I-III)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to compare survival rate at 12 months in Vx-001 treated vs placebo treated patients. El principal objetivo es comparar la tasa de supervivencia global (SG) tras 12 meses con tratamiento con Vx-001 con la de los pacientes tratados con placebo.

Critère d'inclusion

  • non-small cell lung cancer,Cáncer de Pulmón no microcítico

Liens